MENUEdge Therapeutics, Inc
  • Home
  • About
  • Pipeline
  • Contact
  • Investors
  • News
  • Careers

Investors

  • IR Home
  • Stock Information
  • News & Events
  • Financial Information
  • Corporate Governance
  • Investor FAQs
  • Information Request

IR Contact

Primary IR Contact
Gregory Gin
Email: ir@edgetherapeutics.com

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts

Latest News

Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

Read More

Precisa Platform™

Precisa™, our proprietary, programmable, biodegradable polymer-based development platform, enables creation of polymer-based therapeutics capable of delivering directly to the site of injury.

Read More

EG-1962

Our lead product candidate, EG-1962, is a polymer-based microparticle containing nimodipine developed with the Precisa platform to improve patient outcomes after Aneurysmal Subarachnoid Hemorrhage.

Read More
  • Home
  • About
  • Pipeline
  • Contact
  • Investors
  • News

© 2014 Edge Therapeutics, Inc. All Rights Reserved.

300 Connell Drive Suite 4000 Berkeley Heights, NJ 07922

info@edgetherapeutics.com

Terms of Service